Answers are grounded in this paper and cite their sources.
The pyrimidine nucleus is a six-membered aromatic ring in which nitrogen occupies the 1 and 3 positions. It underlies cytosine, thymine and uracil, the building blocks of nucleic acids, and this natural pedigree has made it a favorite framework for medicinal chemists. Both simple and ring-fused pyrimidines show antibacterial, anticancer, antiviral, antitubercular, antifungal and anti-inflammatory properties, and a number of marketed drugs are built on them. The article covers four areas: (i) routes to the ring, from classical condensations to multicomponent, environmentally friendly and metal-catalyzed methods; (ii) the main therapeutic activities, with representative scaffolds, targets and approved drugs; (iii) trends in structure–activity relationships (SAR) at positions 2, 4, 5 and 6 and in fused systems; and (iv) the growing use of docking, molecular dynamics (MD), ADME/ADMET prediction and drug-likeness filters when designing leads. Studies from 2020 to 2026 receive most attention. The review closes with a critical discussion, a list of unresolved gaps and a look ahead. Overall, we argue that progress is most likely when efficient synthesis, thorough biological testing and computational models backed by experimental evidence are pursued together.
No takes yet. Share an insight, caveat, or question.
Madhavi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: